Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from $144 to $154.
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $154
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.